T-knife Therapeutics Expands Board Of Directors With Appointment Of Biotech Executive Christoph Broja

T-knife Therapeutics, Inc., a biopharmaceutical company focused on developing T cell receptor (TCR) engineered T cell therapies to treat cancer, has announced the appointment of Christoph Broja to its Board of Directors. Mr. Broja is a Partner at EQT Life Sciences, based in Munich, where he leads investments in biotechnology, pharmaceuticals, medical devices, and diagnostics. His work centers on early-stage and growth-phase opportunities across the life sciences sector.

Known for his collaborative and inquisitive approach, Mr. Broja brings deep experience and a strategic investor mindset to his board roles. He is actively involved in strengthening the European biotech ecosystem and currently serves as a board member at Tubulis GmbH. In the past, he has also served on the board of Cardior Pharmaceuticals and contributed to several other biotech and healthcare ventures.

Thomas M. Soloway, President and Chief Executive Officer, said, “We are pleased to welcome Christoph to our board of directors. Christoph brings a wealth of experience and insight from years of working at the forefront of biotech investing. EQT Life Sciences stands among Europe’s largest investors in the life sciences sector, with a strong track record of identifying and backing groundbreaking biotech innovations. We are fortunate to have his partnership as we work towards rapidly advancing our supercharged PRAME-targeted TCR-T, TK-6302, into the clinic -- with a CTA submission expected later this year.”

Mr. Broja stated, “T-knife has made remarkable progress developing next-generation technologies to engineer TCR-Ts that address the challenges of T cell fitness and persistence, key factors that have limited the full potential of this modality in the solid tumor setting. I am excited to join the board as the company is in transition to a clinical setting, working to demonstrate that TK-6302’s best-in-class preclinical profile translates into a therapy that delivers deep and durable responses in tumor indications with high unmet need.”

Mr. Soloway mentioned, “I would also like to thank Geraldine O’Keeffe, who is leaving our board, for her steady commitment to the mission of T-knife. We wish Geraldine well as she continues her contributions within a new investment strategy at EQT, and to the important work of building and guiding the next wave of biotech companies that are defined by their mission to make a meaningful impact on patient care.”

Mr. Broja joined EQT Life Sciences in 2022. Before that, he was a Principal at Gurnet Point Capital in Boston, where he helped lead investments in biopharma and molecular diagnostics and held board positions in a number of innovative healthcare companies. Earlier in his career, he worked at B-Flexion Capital in London and began his investment career as an analyst at Franz Haniel & Cie., a private equity firm in Germany. He holds a degree in Business Administration from Friedrich Schiller University Jena and is a Chartered Financial Analyst (CFA). With this appointment, T-knife Therapeutics strengthens its Board with an experienced investor who brings valuable insights into biotech financing, strategic growth, and global healthcare innovation.